🔎 Trials Near Me

Hjem › Kronisk lymfatisk leukæmi › Washington › Seattle

Kronisk lymfatisk leukæmi kliniske forsøg i Seattle, WA

20 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i og omkring Seattle (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
  • Swedish Medical Center-Ballard Campus, Seattle
  • Swedish Medical Center-Cherry Hill, Seattle
  • Swedish Medical Center-First Hill, Seattle
  • og 1 flere
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

RekruttererFase 1/2
  • Research Site, Seattle
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06542250

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

RekruttererFase 3
  • Fred Hutchinson Cancer Center, Seattle
  • Swedish Medical Center-First Hill, Seattle
  • FHCC at Northwest Hospital, Seattle
  • og 1 flere
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

RekruttererFase 1/2
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

RekruttererFase 3
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07277231

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

RekruttererFase 1/2
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06697184

A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

RekruttererFase 3
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06973187

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

RekruttererFase 3
  • Fred Hutchinson Cancer Research Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT07648264

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

RekruttererFase 2
  • Fred Hutchinson Cancer Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07221500

Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT07194980

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

RekruttererFase 1
  • Fred Hutch Cancer Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT06528301

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

RekruttererFase 2Frivillige med god helbredstilstand velkomne
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Alle køn · Opdateret 29. maj 2026 · NCT04195633

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og opefter · Alle køn · Opdateret 18. maj 2026 · NCT04941716

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

RekruttererFase 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Alder 18 og opefter · Alle køn · Opdateret 22. apr. 2026 · NCT06839053

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

RekruttererFase 4
  • Swedish Cancer Institute, Seattle
Alder 18 og opefter · Alle køn · Opdateret 2. mar. 2026 · NCT06876662

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

RekruttererFase 4
  • Swedish Cancer Institute, Seattle
Alder 18 og opefter · Alle køn · Opdateret 2. mar. 2026 · NCT06876649

Study of SGR-1505 in Mature B-Cell Neoplasms

RekruttererFase 1
  • Fred Hutchinson Cancer Center, Seattle
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

RekruttererFase 2
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle
Alder 18 til 80 · Alle køn · Opdateret 14. okt. 2025 · NCT06520098

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

RekruttererFase 1
  • Swedish Cancer Institute, Seattle
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2025 · NCT05780034

Kronisk lymfatisk leukæmi forsøg i andre byer

Andre studier i Seattle

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.